Saudi clinicians face uneven ground in carbapenem-resistant Enterobacterales care
Carbapenem-resistant Enterobacterales infections remain one of the most difficult problems in hospital infectious diseases, and the Saudi Arabian survey captured how physicians and pharmacists are approaching that pressure point in everyday practice. CRE carries a high clinical burden because therapeutic options are limited, the organisms often arise in severely ill patients, and treatment decisions must be made quickly, sometimes before susceptibility data are fully available. In that setting, practice variation is not a minor administrative issue. It can shape whether a patient receives active therapy early enough to matter.
This nationwide cross-sectional survey included 158 physicians and pharmacists from 26 centres across Saudi Arabia. The sample brought together two professional groups that sit at the center of inpatient antimicrobial decision-making, one usually leading diagnosis and bedside management, the other often shaping stewardship, drug selection, dosing support, and supply constraints. Survey domains covered institutional resources, antimicrobial selection, treatment duration, and management of septic shock, which makes the instrument broader than a narrow opinion poll and closer to a real-world map of how CRE care is organized at the point of delivery.
A single feature of the design stands out immediately: the questionnaire was piloted with five physicians and five pharmacists before distribution. That step matters because terminology around resistant Gram-negative infections can be interpreted differently across disciplines, and a poorly phrased survey can blur the line between knowledge gaps and wording problems. Pilot testing increases the chance that answers reflect genuine practice patterns rather than confusion over terms, especially when respondents are asked about escalation strategies, duration of therapy, or the handling of hemodynamic instability in septic shock.
Why CRE exposes differences in hospital practice
The clinical challenge posed by CRE is not simply resistance on a microbiology report. These infections commonly force clinicians to choose between imperfect options, each with different toxicity profiles, pharmacokinetic constraints, and stewardship consequences. A hospital with ready access to infectious diseases expertise, antimicrobial stewardship input, timely susceptibility testing, and critical care support may manage these infections very differently from a smaller centre with fewer specialist resources. Surveying 26 centres gives this study reach across institutional settings, and that breadth is essential when the underlying problem depends so heavily on local infrastructure.
CRE management also demands coordinated decision-making. Physicians may prioritize immediate clinical stabilization, while pharmacists may emphasize dose optimization, drug-drug interactions, renal adjustment, and preservation of limited agents. When those perspectives align, treatment can be more consistent. When they diverge, a patient can experience delays in active therapy, variable treatment lengths, or inconsistent responses to septic shock. In resistant infections, small differences in prescribing behavior can carry large downstream consequences because the therapeutic window is often narrow and the margin for error is thin.
The survey addressed antimicrobial selection directly, which is where bedside uncertainty becomes most visible. CRE infections rarely fit a one-size-fits-all pathway, and choice of therapy is influenced by illness severity, source of infection, local resistance patterns, and availability of agents. Treatment duration adds another layer of complexity, since prolonged courses may expose patients to toxicity and selection pressure, while short courses may be insufficient in complicated infection. The inclusion of septic shock management was especially relevant, because unstable patients require rapid empiric decisions before definitive microbiology arrives. In those cases, institutions need more than drug access; they need an agreed workflow for rapid escalation.
One sentence captures the practical stakes plainly: CRE management depends as much on system design as on microbiology.
Sampling limits and what the survey can and cannot prove
Convenience sampling constrains how far the findings can be generalized. The survey drew participants who were available and willing to respond, which can overrepresent clinicians already interested in CRE or antimicrobial stewardship. There was also no calculable response rate, leaving open the possibility that nonresponders differed in important ways from respondents. In survey research, that missing denominator weakens confidence in how closely the sample mirrors the broader national clinician population.
Self-report introduces another layer of uncertainty. Clinicians may describe what they believe is best practice rather than what occurs during a busy night shift, an understaffed weekend, or a critically ill admission with incomplete laboratory data. Recall bias can distort frequency, duration, and sequencing of decisions. Reporting bias can make practice appear more standardized than it really is. Because the study relied on responses rather than prescription audits or patient-level outcomes, it cannot tell whether reported approaches translated into better cure rates, lower mortality, shorter hospital stays, or fewer adverse events.
Still, a survey of this kind has value precisely because CRE management is shaped by local workflows that often remain invisible in outcome studies. If one centre has strong access to pharmacy support and another depends on ad hoc consultation, the difference may never appear in a registry unless someone asks the clinicians directly. This design captures those front-line realities before they are compressed into administrative data.
Stewardship, expertise, and the problem of variation
The survey’s focus on institutional resources signals an important truth about resistant Gram-negative infection: treatment decisions do not happen in isolation. Antimicrobial stewardship programs, infectious diseases consultation, laboratory turnaround times, and availability of newer agents all affect how CRE is managed. In a pathogen family defined by limited options, variation in these supports can produce variation in care even when clinicians share the same goals.
For Saudi Arabia, the nationwide scope is a strength because it brings attention to a multicentre problem rather than a single-hospital practice pattern. The inclusion of both physicians and pharmacists is equally important. CRE care is inherently interdisciplinary, and discordance between prescriber behavior and pharmacy-led antimicrobial oversight can shape treatment timing, regimen selection, and duration. A survey that looks only at physicians would miss part of the story. A survey that looks only at pharmacists would miss the bedside pressures that drive urgent empiric choices.
The study does not provide patient-level outcomes, and that limits any attempt to judge whether current practices are adequate or harmful. It does, however, document an important operational question: how do clinicians across a broad national sample approach one of the most difficult infection problems in modern inpatient medicine? That question remains central for stewardship policy, institutional training, and future comparative studies that connect reported practice to actual prescribing records and clinical outcomes.
Without those outcome data, the survey serves as a baseline map rather than a verdict. Its greatest value lies in exposing where practice alignment may be strong, where it may be inconsistent, and where future work needs to move from self-report to audited care.
What the survey leaves unanswered at the bedside
The most pressing unanswered issues are concrete. Do hospitals with better CRE infrastructure choose more consistent regimens? Are pharmacists involved early enough to influence empiric therapy in septic shock? Do treatment durations vary by centre, specialty, or level of support? Those are the questions that determine whether a survey can be translated into policy.
Until prescription-level and outcome-level data are linked to these reported practices, the study remains a description of clinician behavior rather than proof of clinical effectiveness. For CRE, that distinction is not abstract. It is the difference between knowing what clinicians say they do and knowing what actually happens when a patient deteriorates in the emergency department, intensive care unit, or surgical ward.